at Benzinga.com (Jan 15, 2015)
Leerink Swann ups Eli Lilly (LLY +5.3%) to Outperform and raises sales estimates on the back of positive trial results for its gastric cancer treatment, ramucirumab. The firm thinks the recently released data shows encouraging potential for use on other tumor types, which could boost sales and lower the drug's overall marketing risk outlook.
From other sites
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs